Skip to main content

Table 2 ME/CFS and Long COVID Clinical Relevancy with AEO

From: Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial

ME/CFS and Long COVID Clinical Relevancy with Anhydrous Enol-Oxaloacetate (% of Treated Patients that reduced the Chalder Fatigue Bimodal Score to 4 or less)
ME/CFS 500 mg BID 21.7%
ME/CFS 1000 mg BID 27.6%
ME/CFS 1000 mg TID 33.3%
Long COVID 500 mg BID 46.8%
Long COVID 1000 mg BID 20.7%